Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision to declare the Wegovy shortage over. Meanwhile, Eli Lilly has done the same in a parallel case over Zepbound’s removal from the FDA shortage list.
